Abstract
Treatment of BCR-ABL(+) human leukemia has been significantly improved by ABL tyrosine kinase inhibitors (TKIs), but they are not curative for most pa......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
